Finally, additional genes which were identified from our MYCN binding analysis have also been recently reported by Vermeulen et al.[48] as part of a 59-gene expression signature which was applied as an accurate predictor of clinical outcome in patients with neuroblastoma. The gene discussed is MYCN; the disease is neuroblastoma.